Castle Biosciences, Inc. (CSTL)Healthcare | Diagnostics & Research | Friendswood, United States | NasdaqGM
33.50 USD
-0.76
(-2.218%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 33.50 |
Hot Take ↕ | Aug. 22, 2026, 5:50 a.m. EDT
Castle Biosciences presents a classic case of a company with impressive top-line growth but fundamentally broken profitability. The business is expanding revenue by over 20%, yet it remains deeply unprofitable with negative operating margins and a forward P/E that is mathematically undefined due to losses. This disconnect creates a fragile valuation; the stock trades at nearly 3x sales despite generating no free cash flow and burning capital. The recent price action shows resilience, bouncing off the 50-day moving average, but the underlying economics do not support a 'buy and hold' thesis without significant risk of dilution or further margin compression. Regarding the short-term outlook, the statistical forecasting model offers a weak lean upward, but this is contradicted by the heavy speculative positioning in deep out-of-the-money puts, which suggests traders are pricing in a potential crash rather than a continuation of the recent rally. The consensus analyst target implies substantial upside, but this relies entirely on the market believing the company can eventually monetize its technology, a leap of faith currently unsupported by the balance sheet or earnings power. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.093598 |
| AutoTheta | 0.107933 |
| AutoETS | 0.108152 |
| AutoARIMA | 0.108154 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 32% |
| H-stat | 10.76 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.059 |
| Excess Kurtosis | 0.84 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 7.797 |
| Revenue per Share | 12.038 |
| Market Cap | 1,023,408,512 |
| Forward P/E | -33.88 |
| Beta | 0.97 |
| Profit Margins | -5.43% |
| Website | https://castlebiosciences.com |
As of Aug. 22, 2026, 5:50 a.m. EDT: Speculators are positioning for a range-bound outcome with a distinct skew toward downside protection. While there is notable call volume at the $40 strike for October expiration suggesting a hope for a rally, the overwhelming majority of open interest and volume in both calls and puts lies deep out-of-the-money (OTM). Specifically, massive put positions exist at strikes significantly below the current price ($12.50, $15.00, $20.00), indicating a fear of a severe decline rather than a belief in a breakout. The implied volatility is extremely low for longer-dated contracts, reflecting a lack of consensus on a major directional move, while the short-term IV spike suggests some nervousness around the immediate earnings date.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.41511774 |
| Address1 | 1,500 W. Parkwood Ave |
| Address2 | Suite 400 |
| All Time High | 107.69 |
| All Time Low | 9.26 |
| Ask | 40.14 |
| Ask Size | 2 |
| Audit Risk | 3 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 398,320 |
| Average Daily Volume3 Month | 403,038 |
| Average Volume | 403,038 |
| Average Volume10Days | 398,320 |
| Beta | 0.974 |
| Bid | 22.02 |
| Bid Size | 2 |
| Board Risk | 6 |
| Book Value | 15.407 |
| City | Friendswood |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 7 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 33.5 |
| Current Ratio | 6.036 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 34.275 |
| Day Low | 32.8 |
| Debt To Equity | 7.797 |
| Display Name | Castle Biosciences |
| Earnings Call Timestamp End | 1,785,443,400 |
| Earnings Call Timestamp Start | 1,785,443,400 |
| Earnings Timestamp | 1,785,441,600 |
| Earnings Timestamp End | 1,793,649,600 |
| Earnings Timestamp Start | 1,793,649,600 |
| Ebitda | -16,516,000 |
| Ebitda Margins | -0.046230003 |
| Enterprise To Ebitda | -48.029 |
| Enterprise To Revenue | 2.22 |
| Enterprise Value | 793,253,504 |
| Eps Current Year | -1.27222 |
| Eps Forward | -0.98889 |
| Eps Trailing Twelve Months | -0.63 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 26.912 |
| Fifty Day Average Change | 6.5879993 |
| Fifty Day Average Change Percent | 0.24479783 |
| Fifty Two Week Change Percent | 41.511772 |
| Fifty Two Week High | 44.28 |
| Fifty Two Week High Change | -10.779999 |
| Fifty Two Week High Change Percent | -0.24345075 |
| Fifty Two Week Low | 17.722 |
| Fifty Two Week Low Change | 15.778 |
| Fifty Two Week Low Change Percent | 0.8903058 |
| Fifty Two Week Range | 17.722 - 44.28 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,564,061,400,000 |
| Float Shares | 27,086,415 |
| Forward Eps | -0.98889 |
| Forward P E | -33.876366 |
| Free Cashflow | -7,256,375 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 1,002 |
| Fullday Change | -0.759998 |
| Fullday Change Percent | -2.21833 |
| Fullday Price | 33.5 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.77258 |
| Gross Profits | 276,025,984 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.02475 |
| Held Percent Institutions | 0.90884 |
| Implied Shares Outstanding | 30,549,507 |
| Industry | Diagnostics & Research |
| Industry Disp | Diagnostics & Research |
| Industry Key | diagnostics-research |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE; AdvanceAD-Tx, a non-invasive GEP test which is designed to guide systemic treatment selection for patients aged 12 years and older with moderateto-severe AD; DecisionDx-SCC, a GEP test for cutaneous squamous cell carcinoma; and MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions. It also provides DecisionDx-UM, a risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company offers its products to dermatology and gastroenterology markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas. |
| Long Name | Castle Biosciences, Inc. |
| Market | us_market |
| Market Cap | 1,023,408,512 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_60295846 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -19,415,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,045,709,624 |
| Number Of Analyst Opinions | 9 |
| Open | 34.02 |
| Operating Cashflow | 42,634,000 |
| Operating Margins | -0.029649999 |
| Overall Risk | 6 |
| Payout Ratio | 0.0 |
| Phone | 866 788 9007 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 33.5 |
| Post Market Time | 1,787,959,806 |
| Previous Close | 34.26 |
| Price Eps Current Year | -26.331923 |
| Price Hint | 2 |
| Price To Book | 2.1743364 |
| Price To Sales Trailing12 Months | 2.8644598 |
| Profit Margins | -0.05434 |
| Quick Ratio | 5.602 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | -0.759998 |
| Regular Market Change Percent | -2.21833 |
| Regular Market Day High | 34.275 |
| Regular Market Day Low | 32.8 |
| Regular Market Day Range | 32.8 - 34.275 |
| Regular Market Open | 34.02 |
| Regular Market Previous Close | 34.26 |
| Regular Market Price | 33.5 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 372,590 |
| Return On Assets | -0.0135699995 |
| Return On Equity | -0.04196 |
| Revenue Growth | 0.201 |
| Revenue Per Share | 12.038 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 30,549,507 |
| Shares Percent Shares Out | 0.0574 |
| Shares Short | 1,753,605 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 1,421,793 |
| Short Name | Castle Biosciences, Inc. |
| Short Percent Of Float | 0.0588 |
| Short Ratio | 3.74 |
| Source Interval | 15 |
| State | TX |
| Symbol | CSTL |
| Target High Price | 57.0 |
| Target Low Price | 35.0 |
| Target Mean Price | 44.0 |
| Target Median Price | 44.0 |
| Total Cash | 266,804,992 |
| Total Cash Per Share | 8.734 |
| Total Debt | 36,650,000 |
| Total Revenue | 357,278,016 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.63 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 29.45585 |
| Two Hundred Day Average Change | 4.0441494 |
| Two Hundred Day Average Change Percent | 0.13729529 |
| Type Disp | Equity |
| Volume | 372,590 |
| Website | https://castlebiosciences.com |
| Zip | 77,546 |